2-5A pentasodium solution (100 mM)  (Synonyms: 2′,5′-ApApA pentasodium; 2′,5′-trioligoadenylate pentasodium; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine pentasodium)

2-5A (2′,5′-ApApA) pentasodium solution 100 mM is a high-affinity (K_a=0.04 nM) RNase L binder. 2-5A pentasodium solution 100 mM activates the nuclease activity of latent RNase L to cleave single-stranded RNA by inducing conformational changes and dimerization of latent RNase L, thereby mediating critical antiviral responses and enhancing interferon effects. 2-5A pentasodium solution 100 mM not only effectively inhibits Rauscher murine leukemia virus replication, reduces viremia and splenomegaly, but also enhances antileukemic efficacy when combined with amphotericin B and exhibits favorable high-dose tolerance. 2-5A pentasodium solution 100 mM is an important tool molecule for investigating the pathological mechanisms of viral infection, hereditary prostate cancer and leukemia^[1][2].

2-5A pentasodium solution 100 mM specifically binds to ankyrin repeat domains 2 and 4 of RNase L (K_0.5=40 pM), induces its dimerization, and activates the RNA cleavage function of RNase L^[1].
Endogenously produced 2-5A activates RNase L in interferon-treated mouse L fibroblasts infected with encephalomyocarditis virus, thereby inducing ribosomal RNA cleavage^[1].
2-5A pentasodium solution 100 mM activates RNase L and induces the expression of the MIC-1 gene in mammalian cells via JNK- and ERK-dependent pathways^[1].
2-5A pentasodium solution 100 mM activates RNase L and induces caspase-dependent apoptosis in mammalian cells via the JNK-mediated pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2-5A pentasodium solution 100 mM (endogenously produced trimeric form p₃(A2'p)₂A; endogenously generated via IFN-induced 2-5A synthetase in response to viral dsRNA) activates RNase L to mediate potent antiviral activity against multiple viral pathogens, induce apoptosis, and trigger antiviral gene transcription in mice^[1].
Synthetic (2’-5’)ApApA (100 μg-1 mg/mouse; i.p.; daily for 5 days or 15 total doses) exhibits dose-dependent antileukaemic activity (up to 26% splenomegaly inhibition) and potent antiviral activity (72% viraemia suppression, >95% RMLV replication inhibition) in RMLV-infected BALB/c male mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1275.50

C₃₀H₃₅N₁₅Na₅O₂₅P₅

Liquid

Colorless to light yellow

NC1=NC=NC2=C1N=CN2[C@H]3[C@H](OP(OC[C@@H](O[C@H]([C@@H]4OP(OC[C@@H](O[C@H]([C@@H]5O)N6C=NC7=C6N=CN=C7N)[C@H]5O)(O[Na])=O)N8C=NC9=C8N=CN=C9N)[C@H]4O)(O[Na])=O)[C@H](O)[C@@H](COP(OP(OP(O)(O[Na])=O)(O[Na])=O)(O[Na])=O)O3

Room temperature in continental US; may vary elsewhere.

Solution, -20°C, 2 years

• [1]. Silverman R H. A scientific journey through the 2-5A/RNase L system[J]. Cytokine & growth factor reviews, 2007, 18(5-6): 381-388.

  [2]. Kara J, Mach O, Smrt J. Antiviral and anticellular effects of synthetic(2'-5')-oligoadenylate(A 2'p 5'A 2'p 5'A) in Rauscher murine leukaemia[J]. Acta virologica, 1983, 27(6): 477-483.